What Is the Latest Treatment for Rheumatoid Arthritis?

Rheumatoid arthritis treatment has expanded well beyond the traditional playbook of methotrexate and steroids, though those older drugs remain the starting point for most people. The newest approved options are oral JAK inhibitors and a growing roster of biologic drugs, while genuinely experimental therapies like CAR T cell infusions and vagus nerve stimulation have produced striking early results in patients who have run out of conventional options. The field is moving fast enough that what counts as “latest” depends on whether you mean the newest drug your rheumatologist can prescribe today or the treatments making headlines in clinical trials.

The Treat-to-Target Framework Still Drives Decisions

Before diving into specific drugs, it helps to understand the strategy that guides how rheumatologists choose and switch treatments. The dominant approach, endorsed by international guidelines for over a decade, is called treat-to-target. The idea is straightforward: pick a measurable goal, usually remission or at least low disease activity, check progress every few months, and escalate therapy if you are not hitting that target. An international task force concluded that remission should be the ultimate goal, with low disease activity as an acceptable alternative mainly for people with long-standing disease who have become resistant to multiple treatments.¹

In practice, most people start on methotrexate, sometimes with a short course of glucocorticoids to bridge the gap while the methotrexate kicks in.² If disease activity remains too high after three to six months, guidelines call for stepping up to a biologic or a targeted synthetic drug. Real-world data from Japan, however, show a gap between what guidelines recommend and what actually happens: many patients stay on methotrexate alone without timely intensification, and long-term glucocorticoid use remains common despite guideline advice against it.³ That pattern is not unique to Japan. Many patients worldwide languish on suboptimal regimens longer than they should.

JAK Inhibitors Changed the Oral Treatment Landscape

The biggest shift in approved RA medications over the past decade has been the arrival of JAK inhibitors, a class of oral pills that block enzymes involved in immune signaling. Tofacitinib was first to market, followed by baricitinib, upadacitinib, and filgotinib (available in some countries). These drugs offer something biologics cannot: you swallow a pill instead of injecting yourself or visiting an infusion center.

Clinical trial data showed that tofacitinib combined with methotrexate was as effective as the widely used biologic adalimumab combined with methotrexate, and tofacitinib alone outperformed methotrexate alone in slowing structural joint damage.⁴ That kind of performance made JAK inhibitors look like a genuine alternative to injectable biologics.

Then came the safety concerns. A large randomized trial comparing tofacitinib to TNF-inhibitor biologics found a higher risk of heart attacks, cancer, and blood clots with tofacitinib, particularly at the higher dose. That trial led the FDA to add class-wide warnings to tofacitinib, baricitinib, and upadacitinib.⁵ A network meta-analysis later found that the elevated mortality risk compared to adalimumab was driven primarily by tofacitinib, while other JAK inhibitors did not show a statistically significant increase.⁶ Post-hoc analysis of the same pivotal trial found that the cardiovascular risk was concentrated in patients over 65 or those with pre-existing heart disease, and that the lower tofacitinib dose carried a risk closer to that of TNF inhibitors.⁷

What this means in practice is that JAK inhibitors are still prescribed widely, but many rheumatologists now reserve them for patients who have tried and failed a biologic first, especially if the patient has cardiovascular risk factors. The risk profile is not identical across the class, so the conversation about which JAK inhibitor to use, and for whom, has become more nuanced than it was a few years ago.

Biologics Remain the Workhorse for Escalated Therapy

Biologic drugs, meaning injectable or infused proteins that target specific parts of the immune system, remain the backbone of treatment when methotrexate is not enough. The main categories are TNF inhibitors (like adalimumab, etanercept, and infliximab), IL-6 receptor inhibitors (tocilizumab and sarilumab), B-cell-depleting agents (rituximab), and T-cell co-stimulation blockers (abatacept). Each targets a different piece of the inflammatory machinery.

When it comes to choosing between TNF inhibitors and IL-6 receptor inhibitors, registry data from biologic-experienced patients show no consistent difference in disease activity outcomes or patient-reported measures between the two classes, whether used alone or combined with methotrexate.⁸ The practical difference often comes down to whether a patient can tolerate methotrexate. TNF inhibitors work best when paired with methotrexate, but a network meta-analysis found that tocilizumab is one of the few biologics that performs just as well on its own as it does in combination.⁹ Abatacept may similarly hold its own without methotrexate in some treatment-refractory patients.¹⁰ For people who cannot stomach methotrexate or have liver concerns, those options matter.

Biosimilars Have Made Biologics More Affordable

One of the most impactful developments for patients is the growing availability of biosimilars, which are near-identical copies of biologic drugs sold at lower prices once the originator’s patent expires. Multiple biosimilars now exist for adalimumab, etanercept, infliximab, and rituximab. A systematic review of real-world studies found that people who started on a biosimilar stayed on treatment at the same rate as those who started on the original, with no meaningful differences in disease activity.¹¹

Some patients worry about being switched from a brand-name biologic to a biosimilar, but a meta-analysis of switching trials found that a single switch produced essentially the same treatment response, disability scores, side-effect rates, and rates of developing antibodies against the drug.¹² This is reassuring and increasingly relevant as insurance plans and healthcare systems push toward biosimilar adoption to control costs.

CAR T Cells for Rheumatoid Arthritis

Perhaps the most headline-grabbing development is the use of CAR T cell therapy, a technique borrowed from cancer medicine. In cancer, engineers reprogram a patient’s own immune cells to attack tumors. In autoimmune disease, the same approach is being used to wipe out the B cells that produce the harmful autoantibodies driving RA. The results so far, while from tiny studies, have been remarkable.

A review of the first ten RA patients treated with CAR T cells targeting B-cell markers reported that nine of the seropositive patients experienced depletion of circulating B cells, disappearance of autoantibodies, and drug-free remission. A tenth patient with seronegative disease initially responded but later relapsed.¹³ The phase 1 portion of a more formal trial, called COMPARE, tested an autologous CD19 CAR T cell product called mivocabtagene autoleucel in six patients with severe, treatment-refractory RA who had failed multiple prior drugs. All six experienced cytokine release syndrome, a known side effect, but it was limited to mild grades. No serious adverse events occurred. Disease activity improved in every patient, with half achieving remission by standard measures, all while off all other RA medications.¹⁴

To be clear, this remains very early-stage. CAR T therapy requires chemotherapy-based conditioning before infusion, carries real risks of immune suppression, and is extraordinarily expensive in its current form. It is being tested only in people who have failed virtually everything else. But the idea that a one-time treatment could produce lasting drug-free remission in a chronic autoimmune disease is genuinely novel, and the phase 2 expansion of the COMPARE trial is underway.

Bispecific Antibodies and BTK Inhibitors in the Pipeline

Two other drug classes are working their way through development. Bispecific antibodies are engineered proteins that can grab onto two different immune targets at once. The logic is that blocking a single pathway leaves others free to drive inflammation, and hitting two simultaneously could produce better results. Preclinical and early clinical data suggest these drugs may improve disease control and potentially help patients who do not respond to existing single-target biologics.¹⁵ One example in preclinical development targets both OX40L and TNF-alpha, two molecules involved in different arms of the inflammatory cascade, and has shown strong dual blockade in animal models of RA.¹⁶ None are approved for RA yet.

BTK inhibitors target Bruton’s tyrosine kinase, an enzyme important for B cell activation and survival. Several candidates, including fenebrutinib and evobrutinib, have been tested in clinical trials for RA.¹⁷ These oral drugs could offer a different mechanism of B cell suppression without the complete B cell depletion seen with rituximab or CAR T therapy. Progress has been slower than initially hoped, and no BTK inhibitor has yet reached approval for RA, but the approach remains active in clinical research.¹⁸

Vagus Nerve Stimulation as a Drug-Free Approach

One of the more unexpected entries in the RA treatment landscape does not involve drugs at all. The vagus nerve, a long nerve running from the brainstem to the gut, has a natural anti-inflammatory function. Stimulating it electrically can dampen the release of inflammatory cytokines.¹⁹

A pivotal randomized controlled trial called RESET-RA tested an implantable vagus nerve stimulation device in 242 RA patients who had already failed biologic or targeted synthetic drugs. At three months, about 35% of patients receiving active stimulation met the primary response benchmark compared to about 24% receiving sham stimulation. Response rates continued climbing in the open-label phase, reaching roughly 53% at 12 months.²⁰ Longer-term follow-up of an earlier pilot study showed that disease activity improvements persisted out to three years, with the majority of patients achieving clinically meaningful improvement, though about half of those responders also added a conventional drug alongside the stimulation.²¹

The response rates are modest compared to biologics, but for patients who have exhausted multiple drug classes, a device-based option with a favorable safety profile fills a real gap. The technology requires a minor surgical implant and regular stimulation sessions, so it is not zero-commitment, but it avoids the systemic immunosuppression that comes with most RA drugs.

Personalized Medicine and Predicting Treatment Response

One of the most frustrating aspects of RA treatment is the trial-and-error involved. A biologic that works brilliantly for one patient does nothing for the next, and it takes months to find out. Researchers are trying to change this by identifying biological markers that predict who will respond to which drug before starting it.

One approach uses tissue from the joint lining itself. A study examining synovial biopsy patterns found that different tissue signatures were associated with different responses to conventional drugs versus biologics. Patients with certain inflammatory cell patterns tended to respond well to standard therapies, while others with different patterns were more likely to need advanced drugs and, worryingly, were also more likely to fail those drugs.²² These findings are still exploratory and did not reach statistical significance in a validation group, but they point toward a future where a biopsy or blood test could guide drug selection from the start.

Machine learning models are also being trained on baseline clinical data to predict who will respond to biologic drugs. In one study, a model achieved high accuracy for predicting initial six-month response, with disease activity score at baseline emerging as the strongest predictor.²³ A broader scoping review of such models found that prediction accuracy varies widely, and boosted-tree and neural-network models tend to perform best, though no single model has become standard clinical practice yet.²⁴ The field is promising but not yet ready for your rheumatologist’s office.

When Treatment Works Well Enough to Scale Back

An underappreciated frontier in RA treatment is figuring out when to dial things down. Biologic drugs are expensive, suppress the immune system, and carry long-term side-effect risks. If someone achieves stable remission, the question becomes whether they can safely reduce or stop their biologic without the disease roaring back.

Evidence suggests that a subset of patients who achieve remission on aggressive therapy can taper off their biologic and maintain what is called biologic-free remission. Some even reach drug-free remission, where all RA medications are stopped and the disease stays quiet.²⁵ This is not possible for everyone, and predicting who can safely taper remains difficult. But pursuing de-escalation where feasible reduces both costs and the cumulative risk of infections and other complications from immunosuppression.

Treating RA Beyond the Joints

RA is a systemic disease, and one of its most serious complications is interstitial lung disease, or RA-ILD, where inflammation and scarring damage the lung tissue. Treatment for RA-ILD has historically been an afterthought, with no randomized trials designed specifically for it until recently. The 2023 ACR/CHEST guideline conditionally recommends mycophenolate, azathioprine, and rituximab as first-line options, with cyclophosphamide and short courses of steroids as alternatives. For patients whose lung disease progresses despite those treatments, antifibrotic drugs like nintedanib and pirfenidone, originally developed for a different form of lung scarring, are conditionally recommended.²⁶

Treatment decisions for RA-ILD involve balancing joint disease activity against lung disease activity. Some drugs that help joints can worsen lung fibrosis, and long-term glucocorticoids, commonly used in RA, actually performed worse than placebo in a trial of patients with a closely related form of lung scarring.²⁶ Antifibrotic therapy is gaining interest as an add-on for patients with progressive fibrotic RA-ILD, especially when the lung scarring pattern resembles that seen in idiopathic pulmonary fibrosis.²⁷ If you have RA and notice unexplained shortness of breath or a persistent dry cough, it is worth raising with your rheumatologist, because lung involvement changes the treatment calculus considerably.

Vaccines and Infection Risk on Immunosuppressive Therapy

Any discussion of RA treatment should acknowledge the trade-off that comes with suppressing the immune system: infections become more common and more dangerous. Staying up to date on vaccinations is one of the simplest and most effective ways to reduce that risk. Influenza, pneumococcal, and herpes zoster vaccines are particularly important for people with RA. The key practical consideration is that live vaccines, like the older shingles vaccine, are generally contraindicated while you are on biologic drugs or higher doses of conventional immunosuppressants.²⁸ The newer recombinant shingles vaccine is not live and can be given safely on most RA regimens. Timing vaccines ideally before starting a biologic, or during a gap in certain therapies, can improve the immune response you get from the shot.

The Gut Microbiome as a Therapeutic Target

Research over the past decade has linked RA to shifts in gut bacteria. People with preclinical RA, meaning they have autoantibodies but have not yet developed joint symptoms, already show altered gut microbiome compositions. Several standard RA drugs themselves change the gut flora, raising the question of whether some of their benefit comes through microbial pathways rather than direct immune suppression.²⁹ The therapeutic promise here is that manipulating gut bacteria through diet, probiotics, or fecal transplant could one day complement existing treatments. That potential has not yet translated into any proven therapy you can ask your doctor for today, but it represents a fundamentally different angle on a disease that has been treated almost exclusively through direct immune suppression.